一瓶中药，撑起一家IPO

Core Viewpoint - Shandong Hanfang Pharmaceutical Co., Ltd. has officially submitted its IPO application to the Hong Kong Stock Exchange, marking the start of its listing process [1][5]. Group 1: Company Overview - The company specializes in combining traditional Chinese medicine with modern science, focusing on medications for skin and mucosal diseases [7]. - Its core product, the "Compound Huangbai Liquid Ointment," ranks fourth in China's external traditional Chinese medicine market with a market share of 1.1% as of 2024 [5][9]. - The product is the only approved prescription ointment in China and is classified as a "national secondary protected Chinese medicine variety," granting it exclusivity in production [9]. Group 2: Financial Performance - The company reported a revenue of 1.053 billion RMB in 2023, with a net profit of 237 million RMB [14]. - For 2024, projected revenue is approximately 992 million RMB, with a net profit of around 199 million RMB [14]. - The gross profit margin for the first nine months of 2025 is estimated to be around 84%, indicating high profitability, although the company heavily relies on a single product for over 90% of its revenue [14][17]. Group 3: Ownership and Management - The company is controlled by the Qin brothers, Qin Wenji (Chairman) and Qin Yinjing (General Manager), who are the founders and major shareholders [22]. - Family members, including their sister and children, also hold roles within the company, indicating a family-run business structure [23]. Group 4: IPO Purpose and Structure - The IPO aims to convert some existing shares into H-shares for trading in Hong Kong while also issuing new H-shares [25]. - The company plans to conduct a share split (1 share into 10 shares) to lower the share price before the listing [26]. - Only the newly issued and some converted H-shares will count as public shares post-IPO to meet the liquidity requirements of the Hong Kong Stock Exchange [26].